3 results
Approved WMOPending
Our primary objective is to investigate the effects of endotoxin-induced systemic inflammation and subsequent development of endotoxin tolerance on the inflammatory response following Fluenz® administration in vivo. To evaluate whether these effects…
Approved WMOCompleted
To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in…
Approved WMORecruiting
To assess safety and tolerability of AMX0035 for treatment of ALS.